High-Dose Prexige Withdrawn in New Zealand

Drug Industry Daily
A A
New Zealand’s drug regulatory authority, Medsafe, has canceled the registration of 200- and 400-mg tablets of the Cox-2 inhibitor Prexige after reviewing local and international reports of severe liver damage in patients taking high doses of the drug, Medsafe announced.

To View This Article:

Login

Subscribe To Drug Industry Daily